These nitrosamine carcinogens are formed from nicotine and related compounds by a nitrosation reaction that occurs during the curing and processing of tobacco. They are called tobacco-specific nitrosamines because they are found only in tobacco products, and possibly in some other nicotine-containing products. The tobacco-specific nitrosamines are present in cigarette smoke and to a lesser degree in "smokeless" tobacco products such as dipping tobacco and chewing tobacco; additional information has shown that trace amounts of NNN and NNK have been detected in e-cigarettes. They are present in trace amounts in snus, a Swedish style snuff that is not fermented (a type of curing) and is pasteurized. They are among the most important carcinogens in cigarette smoke, along with combustion products and other carcinogens.
Among the tobacco-specific nitrosamines, nicotine-derived nitrosamine ketone (NNK) and N-nitrosonornicotine (NNN) are the most carcinogenic. Others include N′-nitrosoanatabine (NAT) and N-nitrosoanabasine (NAB). NNK and its metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) are potent systemic lung carcinogens in rats. Tumors of the nasal cavity, liver, and pancreas are also observed in NNK- or NNAL-treated rats. NNN is an effective esophageal carcinogen in the rat, and induces respiratory tract tumors in mice, hamsters, and mink. A mixture of NNK and NNN caused oral tumors when swabbed in the rat oral cavity. Thus, considerable evidence supports the role of tobacco-specific nitrosamines as important causative factors for cancers of the lung, pancreas, esophagus, and oral cavity in people who use tobacco products.
Human metabolism of NNK and NNN varies widely from individual to individual, and current research is attempting to identify those individuals who are particularly sensitive to the carcinogenic effects of these compounds. Such individuals would be at higher risk for cancer when they use tobacco products or are exposed to secondhand smoke. Identification of high-risk individuals could lead to improved methods of prevention of tobacco-related cancer, and improved risk valuation for insurers.
- Stephen S. Hecht. "Metabolism of Carcinogenic Tobacco-Specific Nitrosamines". National Cancer Institute.
- Goniewicz ML, Knysak J, Gawron M, Kosmider L, Sobczak A, Kurek J, Prokopowicz A, Jablonska-Czapla M, Rosik-Dulewska C, Havel C, Jacob P, Benowitz N (2014). "Levels of selected carcinogens and toxicants in vapour from electronic cigarettes". Tobacco Control 23 (2): 133–9. doi:10.1136/tobaccocontrol-2012-050859. PMC 4154473. PMID 23467656.
- "First identification of a strong oral carcinogen in smokeless tobacco" (Press release). American Chemical Society. August 22, 2012. Retrieved November 30, 2015.
This article is based in part on public domain text taken from an article on the website of the National Cancer Institute, a U.S. Federal Government agency
- "Carcinogens Form from Third-Hand Smoke". ScienceDaily. February 9, 2010.